TGA registration of biologic

Posted 5 years ago

The Therapeutic Goods Administration (TGA) has approved registration of the first biologic for atopic dermatitis in Australia.

Dupilumab (Dupixent® – Sanofi Genzyme) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy.  Dupilumab is not currently listed on the Pharmaceutical Benefits Scheme. Treatment should be initiated and supervised by a dermatologist or immunologist.

For more information, visit the TGA website or view Sanofi Genzyme’s public statement.